Management Team

Jane Chung, R.Ph. has over 20 years of pharmaceutical and biotechnology experience. Ms. Chung has served as our Chief Executive Officer and member of the Board of Directors since March 2025. Previously our President and Chief Operating Officer since December 2023 and our Chief Commercial Officer since August 2021. From 2015 to 2021, Ms. Chung served in several leadership roles at AstraZeneca, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Prior to that, from 2013 to 2015, Ms. Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From 2003 to 2013, she served in various commercial roles for Genentech, Inc., including as Commercial Operations Manager, Division Manager and Senior Marketing Manager. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc. and on non-profit boards in the science, education, and community development arenas. Ms. Chung received her B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John's University, New York.

Edward Albini has served as our Chief Financial Officer since January 2013. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.

Dr. Leyman joined Sutro in 2024 and she brought 20 years of deal making experience in life sciences to the company. Prior to Sutro, she worked at GenEdit, where she oversaw business development, alliance management and corporate strategy. At GenEdit, she successfully led the business development efforts towards the execution of the multiyear collaboration and license agreement with Genentech for a total deal value of $644M. Prior to joining GenEdit, she held positions of increasing responsibility in business development and corporate strategy at Lyell Immunopharma and Calico Life Sciences. In those positions, she led licensing, R&D collaborations and co-development transactions through due diligence, negotiation and execution. She obtained the best performance award of 2020 at Lyell Immunopharma. Prior to joining industry, she led the life sciences team at LRM, a venture capital fund, where she managed investment transactions in biotech companies and was a director on the board of 3 biotech companies (Apitope, Amakem and Complix). She started her business career as Licensing and New Ventures Manager at the Flanders Institute for Biotechnology (VIB), a biotech translational research institute. Dr. Leyman is trained as a molecular biology scientist and published a first author manuscript in Science. She obtained a PhD in Molecular Biology from Imperial College at Wye, London University, UK and a Master’s degree in Chemistry and Biotechnology from Ghent University, Belgium.​

Dr. Hans-Peter Gerber brings 30 years of R&D experience in oncology drug development, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built successful drug development teams across pharma, biotech, and startups, overseeing preclinical development with low clinical attrition rates. Notably, he has contributed to the development of 6 of the 15 approved ADCs.

In September 2023, Hans-Peter joined Sutro Biopharma as CSO, leading a research team of 80 FTEs. He co-founded Codeable Therapeutics in 2022, focusing on next-generation ADCs that induce immunogenic cell death, and successfully secured seed funding in 2023.

Hans-Peter also serves as Chairman of the Board at T-CURX, a startup in Wuerzburg, Germany, developing next-generation CAR-T cell therapies, and serves as a board member at Athebio in Zurich, Switzerland, which develops biotherapeutic compounds using Darpin technology.

From 2018 to 2022, he was CSO and SVP at 3T Biosciences, where he expanded the research organization to over 30 FTEs and raised over $50M in an oversubscribed Series A round as interim CEO. He also served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim for $1.5B in 2021.

Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, leading to its acquisition by Takeda for $525M in 2021. He is a consultant to VC firms, evaluating therapeutic modalities including ADCs, bispecifics, and T-cell programs.

Between 1995 and 2017, Hans-Peter held increasing responsibilities at Genentech, Seattle Genetics, and Pfizer, overseeing multiple oncology biotherapeutic programs from discovery through IND filings. His work led to over 10 IND filings, including 7 ADCs and contributions to 3 BLAs, including Avastin and 2 ADCs (Mylotarg, Besponsa).

As an internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed papers and holds over 100 patents. He received his MS in Biochemistry and PhD in Molecular Biology from the University of Zurich, Switzerland.

Mr. Pauling joined Sutro in 2011 and has since held positions of increasing responsibility, including Intellectual Property Counsel, Associate General and Senior Intellectual Property Counsel, Executive Director of Legal Affairs, and most recently General Counsel. Prior to joining Sutro, Mr. Pauling practiced law at Jones Day and at Pennie & Edmonds, LLP. Mr. Pauling received his J.D. from Santa Clara University School of Law (magna cum laude), and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

Venkatesh Srinivasan, Ph.D. has served as our Chief Technical Operations Officer since May 2023. From April 2022 to May 2023, Dr. Srinivasan served as our Senior Vice President, Process, Analytical and Formulation Development. Prior to that, from March 2011 to March 2022, Dr. Srinivasan worked at Bayer AG, where he was most recently, the Vice President of Global Manufacturing Sciences and Technology. Dr. Srinivasan also co-founded GlycoRx Partners, LLC, a company focused on developing novel, half-life extended pharmaceutical proteins and peptides based on a unique glycoengineering platform, where he was a partner from 2009 to 2011. Prior to that, Dr. Srinivasan worked for Phyton Biotech, LLC where he served as Senior Director, Bioprocess Development and Director, Business Development. Dr. Srinivasan received his B.S. in Chemical Engineering from Indian Institute of Technology, Chennai, and his Ph.D. in Chemical Engineering from the State University of New York. He also held post-doctoral appointments at the School of Engineering, Cornell University, and at the Antibody Engineering Laboratory, University of California, Davis.